We have previously observed that pyridoxine treatment reduced plasma total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol concentrations and increased antithrombin III (AT III) activity in atherosclerotic patients with subnormal plasma pyridoxal 5-phosphate (PLP) levels. In order to confirm these results, we selected 17 males with low plasma PLP levels from a group of 122 80-year-old males in whom PLP has been determined. After supplementation with 120 mg of pyridoxine per day for 8 weeks their mean plasma TC and LDL cholesterol concentrations were decreased by 10% (p less than 0.01) and 17% (p less than 0.001), respectively. There was no effect on high-density lipoprotein cholesterol and triglycerides but plasma AT III activity was increased by 6% (p less than 0.05). The mechanism by which pyridoxine acts is unclear but it is hypothesized that pyridoxine-derived PLP may enhance the catabolism of LDL and the activity of AT III by inhibiting their glycosylation.
|Number of pages||5|
|Journal||Scandinavian Journal of Clinical & Laboratory Investigation|
|Publication status||Published - 1990 Dec|
Bibliographical noteThe information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Neurology, Malmö (013027010), Division of Geriatric Medicine (013040040), Clinical Coagulation Research Unit (013242510), Division of Clinical Chemistry and Pharmacology (013250300)
Subject classification (UKÄ)
- Gerontology, specializing in Medical and Health Sciences
- Pharmacology and Toxicology
- Cardiac and Cardiovascular Systems
- Medicinal Chemistry
- pyridoxal 5-phosphate
- antithrombin III
- low-density lipoproteins